Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

uPAR peptide antagonist alters regulation of MAP kinases and Bcl-2 family members in favor of apoptosis in MDA-MB-231 cell line.

Tarighi P, Montazeri H, Khorramizadeh MR, Sobhani AM, Ostad SN, Ghahremani MH.

Res Pharm Sci. 2015 May-Jun;10(3):200-5.

2.

Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours.

Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES, Krohn M, Selfors LM, Liu W, Chen K, Yong M, Buchwald P, Wang B, Hale KS, Cohick E, Sergent P, Witt A, Kozhekbaeva Z, Gao S, Agoston AT, Merritt MA, Foster R, Rueda BR, Crum CP, Brugge JS, Mills GB.

Nat Commun. 2015 Jun 17;6:7419. doi: 10.1038/ncomms8419.

3.

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.

Teh JL, Shah R, La Cava S, Dolfi SC, Mehta MS, Kongara S, Price S, Ganesan S, Reuhl KR, Hirshfield KM, Karantza V, Chen S.

Breast Cancer Res Treat. 2015 May;151(1):57-73. doi: 10.1007/s10549-015-3365-8.

4.

Radiotherapy-induced plasticity of prostate cancer mobilizes stem-like non-adherent, Erk signaling-dependent cells.

Kyjacova L, Hubackova S, Krejcikova K, Strauss R, Hanzlikova H, Dzijak R, Imrichova T, Simova J, Reinis M, Bartek J, Hodny Z.

Cell Death Differ. 2015 Jun;22(6):898-911. doi: 10.1038/cdd.2014.97.

5.

A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Ling X, Cao S, Cheng Q, Keefe JT, Rustum YM, Li F.

PLoS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571.

6.

Targeting the regulatory machinery of BIM for cancer therapy.

Harada H, Grant S.

Crit Rev Eukaryot Gene Expr. 2012;22(2):117-29.

7.

Bim is required for T-cell allogeneic responses and graft-versus-host disease in vivo.

Yu Y, Yu J, Iclozan C, Kaosaard K, Anasetti C, Yu XZ.

Am J Blood Res. 2012;2(1):77-85.

8.

N-cadherin mediates neuronal cell survival through Bim down-regulation.

Lelièvre EC, Plestant C, Boscher C, Wolff E, Mège RM, Birbes H.

PLoS One. 2012;7(3):e33206. doi: 10.1371/journal.pone.0033206.

9.

ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity.

Shao Y, Aplin AE.

Cell Death Dis. 2012 Jan 19;3:e253. doi: 10.1038/cddis.2011.137.

10.

The MEK-ERK pathway negatively regulates bim expression through the 3' UTR in sympathetic neurons.

Hughes R, Gilley J, Kristiansen M, Ham J.

BMC Neurosci. 2011 Jul 15;12:69. doi: 10.1186/1471-2202-12-69.

11.

CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through Bim-mediated intrinsic apoptosis.

Drury LJ, Wendt MK, Dwinell MB.

PLoS One. 2010 Sep 22;5(9):e12895. doi: 10.1371/journal.pone.0012895.

12.

Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.

Warrington NM, Gianino SM, Jackson E, Goldhoff P, Garbow JR, Piwnica-Worms D, Gutmann DH, Rubin JB.

Cancer Res. 2010 Jul 15;70(14):5717-27. doi: 10.1158/0008-5472.CAN-09-3769.

13.

Interleukin-7 regulates Bim proapoptotic activity in peripheral T-cell survival.

Li WQ, Guszczynski T, Hixon JA, Durum SK.

Mol Cell Biol. 2010 Feb;30(3):590-600. doi: 10.1128/MCB.01006-09.

14.

PI-3 kinase activity is necessary for ERK1/2-induced disruption of mammary epithelial architecture.

Pearson GW, Hunter T.

Breast Cancer Res. 2009;11(3):R29. doi: 10.1186/bcr2259.

15.

Uncoupling of the LKB1-AMPKalpha energy sensor pathway by growth factors and oncogenic BRAF.

Esteve-Puig R, Canals F, Colomé N, Merlino G, Recio JA.

PLoS One. 2009;4(3):e4771. doi: 10.1371/journal.pone.0004771.

16.

Silencing of TMS1/ASC promotes resistance to anoikis in breast epithelial cells.

Parsons MJ, Patel P, Brat DJ, Colbert L, Vertino PM.

Cancer Res. 2009 Mar 1;69(5):1706-11. doi: 10.1158/0008-5472.CAN-08-2351.

17.

A protein kinase Cdelta-dependent protein kinase D pathway modulates ERK1/2 and JNK1/2 phosphorylation and Bim-associated apoptosis by asbestos.

Buder-Hoffmann SA, Shukla A, Barrett TF, MacPherson MB, Lounsbury KM, Mossman BT.

Am J Pathol. 2009 Feb;174(2):449-59. doi: 10.2353/ajpath.2009.080180.

18.

Transforming growth factor beta (TGFbeta)-induced apoptosis: the rise & fall of Bim.

Ramesh S, Wildey GM, Howe PH.

Cell Cycle. 2009 Jan 1;8(1):11-7. Review.

19.

Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.

Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, Chell SD, Balmanno K, Pritchard CA, Cook SJ.

Oncogene. 2008 Dec 4;27(57):7150-61. doi: 10.1038/onc.2008.335.

20.

Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.

Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M.

Pigment Cell Melanoma Res. 2008 Oct;21(5):534-44. doi: 10.1111/j.1755-148X.2008.00491.x.

Items per page

Supplemental Content

Support Center